PPARγ agonists-Antidiabetic drugs with a potential role in the treatment of diseases other than diabetes

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The use of thiazolidinediones (TZDs) for treating patients with type 2 diabetes mellitus (T2DM) has been expansively increasing. Although troglitazone was withdrawn from the market, rosiglitazone and pioglitazone are currently available in several countries worldwide. Insulin resistance is one of the major pathophysiological alterations in T2DM and can be decreased by using TZDs. TZDs can be used in combination with other oral antidiabetic drugs, preferably with metformin or sulfonylureas. The effects of TZDs are explained by their peroxisome proliferator activator receptor-γ (PPARγ) activating characteristics. Activation of PPARγ leads to lowering blood glucose in diabetic patients but this mechanism may also result in prevention of T2DM. TZDs due to their specific PPARγ activation can be used for reducing cardiovascular risk and even for decreasing certain cardiovascular events. In addition, TZDs are considered promising for the treatment of patients with clinical conditions other than diabetes. Some of the benefits of TZDs have been documented by randomised controlled clinical trials while others are still to be proven. TZDs have well characterised side effects, therefore the benefit-risk ratio should carefully be evaluated.

Original languageEnglish
JournalDiabetes Research and Clinical Practice
Volume78
Issue number3 SUPPL.
DOIs
Publication statusPublished - Dec 20 2007

Fingerprint

Peroxisome Proliferators
Thiazolidinediones
Hypoglycemic Agents
Type 2 Diabetes Mellitus
rosiglitazone
pioglitazone
troglitazone
Therapeutics
Metformin
Insulin Resistance
Blood Glucose
Randomized Controlled Trials
Odds Ratio

Keywords

  • Cardiovascular complications
  • Diabetes prevention
  • Insulin resistance
  • Pioglitazone
  • Rosiglitazone
  • Thiazolidinediones
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{c70400c7bff142dab6718d3626308c7e,
title = "PPARγ agonists-Antidiabetic drugs with a potential role in the treatment of diseases other than diabetes",
abstract = "The use of thiazolidinediones (TZDs) for treating patients with type 2 diabetes mellitus (T2DM) has been expansively increasing. Although troglitazone was withdrawn from the market, rosiglitazone and pioglitazone are currently available in several countries worldwide. Insulin resistance is one of the major pathophysiological alterations in T2DM and can be decreased by using TZDs. TZDs can be used in combination with other oral antidiabetic drugs, preferably with metformin or sulfonylureas. The effects of TZDs are explained by their peroxisome proliferator activator receptor-γ (PPARγ) activating characteristics. Activation of PPARγ leads to lowering blood glucose in diabetic patients but this mechanism may also result in prevention of T2DM. TZDs due to their specific PPARγ activation can be used for reducing cardiovascular risk and even for decreasing certain cardiovascular events. In addition, TZDs are considered promising for the treatment of patients with clinical conditions other than diabetes. Some of the benefits of TZDs have been documented by randomised controlled clinical trials while others are still to be proven. TZDs have well characterised side effects, therefore the benefit-risk ratio should carefully be evaluated.",
keywords = "Cardiovascular complications, Diabetes prevention, Insulin resistance, Pioglitazone, Rosiglitazone, Thiazolidinediones, Type 2 diabetes",
author = "G. Jermendy",
year = "2007",
month = "12",
day = "20",
doi = "10.1016/j.diabres.2007.09.017",
language = "English",
volume = "78",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "3 SUPPL.",

}

TY - JOUR

T1 - PPARγ agonists-Antidiabetic drugs with a potential role in the treatment of diseases other than diabetes

AU - Jermendy, G.

PY - 2007/12/20

Y1 - 2007/12/20

N2 - The use of thiazolidinediones (TZDs) for treating patients with type 2 diabetes mellitus (T2DM) has been expansively increasing. Although troglitazone was withdrawn from the market, rosiglitazone and pioglitazone are currently available in several countries worldwide. Insulin resistance is one of the major pathophysiological alterations in T2DM and can be decreased by using TZDs. TZDs can be used in combination with other oral antidiabetic drugs, preferably with metformin or sulfonylureas. The effects of TZDs are explained by their peroxisome proliferator activator receptor-γ (PPARγ) activating characteristics. Activation of PPARγ leads to lowering blood glucose in diabetic patients but this mechanism may also result in prevention of T2DM. TZDs due to their specific PPARγ activation can be used for reducing cardiovascular risk and even for decreasing certain cardiovascular events. In addition, TZDs are considered promising for the treatment of patients with clinical conditions other than diabetes. Some of the benefits of TZDs have been documented by randomised controlled clinical trials while others are still to be proven. TZDs have well characterised side effects, therefore the benefit-risk ratio should carefully be evaluated.

AB - The use of thiazolidinediones (TZDs) for treating patients with type 2 diabetes mellitus (T2DM) has been expansively increasing. Although troglitazone was withdrawn from the market, rosiglitazone and pioglitazone are currently available in several countries worldwide. Insulin resistance is one of the major pathophysiological alterations in T2DM and can be decreased by using TZDs. TZDs can be used in combination with other oral antidiabetic drugs, preferably with metformin or sulfonylureas. The effects of TZDs are explained by their peroxisome proliferator activator receptor-γ (PPARγ) activating characteristics. Activation of PPARγ leads to lowering blood glucose in diabetic patients but this mechanism may also result in prevention of T2DM. TZDs due to their specific PPARγ activation can be used for reducing cardiovascular risk and even for decreasing certain cardiovascular events. In addition, TZDs are considered promising for the treatment of patients with clinical conditions other than diabetes. Some of the benefits of TZDs have been documented by randomised controlled clinical trials while others are still to be proven. TZDs have well characterised side effects, therefore the benefit-risk ratio should carefully be evaluated.

KW - Cardiovascular complications

KW - Diabetes prevention

KW - Insulin resistance

KW - Pioglitazone

KW - Rosiglitazone

KW - Thiazolidinediones

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=36549070563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549070563&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2007.09.017

DO - 10.1016/j.diabres.2007.09.017

M3 - Article

AN - SCOPUS:36549070563

VL - 78

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 3 SUPPL.

ER -